Kitakaze M, Hori M, Sato H, Iwakura K, Gotoh K, Inoue M, Kitabatake A, Kamada T
First Department of Medicine, Osaka University School of Medicine, Japan.
Circ Res. 1991 May;68(5):1322-39. doi: 10.1161/01.res.68.5.1322.
This study was undertaken to elucidate whether alpha-1 adrenoceptor activity is beneficial to contractile dysfunction during reperfusion after a brief period of ischemia (stunned myocardium) in 54 open-chest dogs. Contractile dysfunction assessed by fractional shortening (FS) was observed 3 hours after the onset of reperfusion following 15 minutes of complete occlusion of the left anterior descending coronary artery. Pretreatment with prazosin (4 micrograms/kg/min i.c.) further deteriorated contractile dysfunction compared with the untreated condition (12.7 +/- 0.6% versus 6.9 +/- 0.4% with prazosin treatment, p less than 0.001). Conversely, alpha 1-adrenoceptor agonists, methoxamine (1.0 microgram/kg/min i.c.) and norepinephrine (0.24 microgram/kg/min i.c.) with rauwolscine and propranolol, significantly attenuated contractile dysfunction (FS in the methoxamine-treated group, 17.3 +/- 0.3%, p less than 0.001 versus the untreated group; FS in the norepinephrine-treated group, 18.0 +/- 0.9%, p less than 0.05 versus 13.6 +/- 1.1% in the propranolol group). Both adenosine release and hyperemic coronary flow response during the early reperfusion period were significantly attenuated in the prazosin-treated group, and both were enhanced in the alpha 1-adrenoceptor stimulation groups. These results suggest that beneficial effects of alpha 1-adrenoceptor activity may be due to the enhanced release of adenosine. To test the cause-effect relation between the extent of adenosine release and contractile dysfunction during reperfusion, 8-phenyltheophylline was infused to block adenosine receptors in the methoxamine-treated group. The treatment with 8-phenyltheophylline completely abolished (FS, 7.4 +/- 0.3%) the beneficial effect of the enhanced adenosine release by alpha 1-adrenoceptor stimulation. Furthermore, in the prazosin-treated group, adenosine (9 micrograms/kg/min) was additionally infused into the left anterior descending coronary artery 5 minutes before and 2 hours after the onset of reperfusion. Both hyperemic coronary flow and contractile dysfunction (FS, 17.3 +/- 0.3%) recovered to the levels of the alpha 1-adrenoceptor stimulation groups. However, treatment with papaverine could not prevent deleterious effects of prazosin despite the fact that comparable hyperemic flow was obtained. Instead, lactate production up to 10 minutes after the onset of reperfusion was significantly larger (p less than 0.01) despite augmented contractile function in the prazosin-treated and the 8-phenyltheophylline with methoxamine-treated groups compared with the untreated group. The electron microscopic examination revealed no irreversible myocardial injury with and without pharmacological interventions. Thus, we conclude that alpha 1-adrenoceptor activity can reduce the magnitude of myocardial stunning and that its cellular mechanism is due to enhanced adenosine release by alpha 1-adrenoceptor activity.(ABSTRACT TRUNCATED AT 400 WORDS)
本研究旨在阐明在54只开胸犬短暂缺血(心肌顿抑)后再灌注期间,α1肾上腺素能受体活性对收缩功能障碍是否有益。在左前降支冠状动脉完全闭塞15分钟后开始再灌注3小时,通过缩短分数(FS)评估收缩功能障碍。与未治疗组相比,哌唑嗪预处理(4微克/千克/分钟,腹腔注射)使收缩功能障碍进一步恶化(未治疗组为12.7±0.6%,哌唑嗪治疗组为6.9±0.4%,p<0.001)。相反,α1肾上腺素能受体激动剂甲氧明(1.0微克/千克/分钟,腹腔注射)和去甲肾上腺素(0.24微克/千克/分钟,腹腔注射)联合利血平与普萘洛尔,显著减轻收缩功能障碍(甲氧明治疗组的FS为17.3±0.3%,与未治疗组相比p<0.001;去甲肾上腺素治疗组的FS为18.0±0.9%,与普萘洛尔组的13.6±1.1%相比p<0.05)。哌唑嗪治疗组在再灌注早期腺苷释放和充血性冠状动脉血流反应均显著减弱,而α1肾上腺素能受体刺激组两者均增强。这些结果表明,α1肾上腺素能受体活性的有益作用可能归因于腺苷释放增加。为了测试再灌注期间腺苷释放程度与收缩功能障碍之间的因果关系,在甲氧明治疗组中注入8-苯甲基黄嘌呤以阻断腺苷受体。8-苯甲基黄嘌呤治疗完全消除了α1肾上腺素能受体刺激增强腺苷释放的有益作用(FS为7.4±0.3%)。此外,在哌唑嗪治疗组中,在再灌注开始前5分钟和开始后2小时,向左前降支冠状动脉额外注入腺苷(9微克/千克/分钟)。充血性冠状动脉血流和收缩功能障碍(FS为17.3±0.3%)均恢复到α1肾上腺素能受体刺激组的水平。然而,尽管获得了相当的充血性血流,但罂粟碱治疗并不能预防哌唑嗪的有害作用。相反,与未治疗组相比,哌唑嗪治疗组以及8-苯甲基黄嘌呤与甲氧明治疗组在再灌注开始后长达10分钟的乳酸生成显著增加(p<0.01),尽管收缩功能有所增强。电子显微镜检查显示,有无药物干预均未发现不可逆的心肌损伤。因此,我们得出结论,α1肾上腺素能受体活性可减轻心肌顿抑的程度,其细胞机制是α1肾上腺素能受体活性增强了腺苷释放。(摘要截短至400字)